• GuruFocus.com

    Orkla ASA's Dividend Analysis

    Orkla ASA (ORKLY) recently announced a dividend of $0.56 per share, payable on 2024-05-13, with the ex-dividend date set for 2024-04-19. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Orkla ASA's dividend performance and assess its sustainability.

  • Reuters

    Weight-loss drug developer Metsera raises $290 million in funding

    Weight-loss drug developer Metsera has raised $290 million in funding, led by biotech investor ARCH Venture Partners as well as participation from firms such as SoftBank and Mubadala Capital, the company said on Thursday. The funding comes at a time when multiple drug companies are competing to grab a slice of the weight-loss drug market, which is estimated by analysts to reach at least $100 billion by the end of the decade. Novo Nordisk and Eli Lilly are so far leading with their powerful and highly popular new GLP-1 drugs Wegovy and Zepbound, respectively.

  • GuruFocus.com

    APA Corp's Dividend Analysis

    APA Corp (NASDAQ:APA) recently announced a dividend of $0.25 per share, payable on 2024-05-22, with the ex-dividend date set for 2024-04-19. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into APA Corp's dividend performance and assess its sustainability.